CHILDRENS MERCY HOSPITAL
- Type
- Teaching hospital
- Where
- KANSAS CITY, MO
- Medicare CCN
- 263302
- Received
- $3,006,610 in 465 records, 2019 ($115,255 general, $2,891,354 research)
- Source
- CMS Open Payments search ↗
On this site
- Business registration: THE CHILDRENS MERCY HOSPITAL CORPORATION Fuzzy (name and state)
- Federal award recipient: CHILDRENS MERCY HOSPITAL Fuzzy (name and state)
- Nonprofit: CHILDRENS MERCY HOSPITAL Fuzzy (name and state)
By year
| Program year | Kind | Records | Amount |
|---|---|---|---|
| 2019 | General payment | 43 | $115,255 |
| 2019 | Research payment | 422 | $2,891,354 |
By company
By nature of payment
| Nature | Records | Amount |
|---|---|---|
| Research payment | 422 | $2,891,354 |
| Education | 4 | $69,306 |
| Space rental or facility fees (teaching hospital only) | 32 | $33,130 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a v | 1 | $8,310 |
| Gift | 3 | $3,717 |
| Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing | 1 | $500 |
| Consulting Fee | 1 | $150 |
| Food and Beverage | 1 | $141 |
Records
| Date | Company | Amount | Nature | Form | Product | Study | Year |
|---|---|---|---|---|---|---|---|
| 2019-12-31 | BioFire Diagnostics, LLC | $40,500 | Research payment | In-kind items and services | FilmArray System Device, Clinical Diagnostics | FilmArray GI Swab Pivotal Study | 2019 |
| 2019-12-31 | Allergan, Inc. | $495 | Research payment | Cash or cash equivalent | LINZESS Drug, GASTROENTEROLOGY | A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, SAFETY AND EFFIACY STUDY OF A RANGE OF LINA | 2019 |
| 2019-12-31 | Allergan, Inc. | $124 | Research payment | Cash or cash equivalent | BOTOX COSMETIC Biological | BOTOX Treatment in Pediatric Lower Limb Spasticity Open-label Study | 2019 |
| 2019-12-31 | AstraZeneca UK Limited | $74 | Research payment | In-kind items and services | BYDUREON Drug, Cardiovascular and Metabolism | A Phase 3 Double Blind Placebo Controlled Randomized Multi Center Study To Assess the Safety and Efficacy of Exenatide O | 2019 |
| 2019-12-30 | BioFire Diagnostics, LLC | $14,381 | Research payment | Cash or cash equivalent | FilmArray System Device, Clinical Diagnostics | FilmArray GI Swab Pivotal Study | 2019 |
| 2019-12-30 | BioFire Diagnostics, LLC | $1,429 | Research payment | In-kind items and services | SpotFire System Device, Clinical Diagnostics | SpotFire RST Pivotal Study | 2019 |
| 2019-12-25 | Amgen Inc. | $1,800 | Research payment | Cash or cash equivalent | Aimovig Biological, Neuroscience | Phase P3 Pediatric Study (EM) | 2019 |
| 2019-12-25 | Amgen Inc. | $1,800 | Research payment | Cash or cash equivalent | Aimovig Biological, Neuroscience | Ph3 Pediatric CM Study | 2019 |
| 2019-12-24 | Amgen Inc. | $5,038 | Research payment | Cash or cash equivalent | Parsabiv Biological, Nephrology | Pediatric Multi-Dose | 2019 |
| 2019-12-23 | PFIZER INC. | $2,112 | Research payment | Cash or cash equivalent | A PHASE 3 MULTICENTER RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED PARALLELGROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY O | 2019 | |
| 2019-12-21 | Amgen Inc. | $4,809 | Research payment | Cash or cash equivalent | Aimovig Biological, Neuroscience | P1b study in children and adolescents with migraine | 2019 |
| 2019-12-21 | PFIZER INC. | $249 | Research payment | Cash or cash equivalent | PREVNAR - 13 Biological, VACCINES | A PHASE 2 RANDOMIZED OPENLABEL TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A MULTIVALENT PNEUMOCOCCAL CONJUGATE V | 2019 |
| 2019-12-20 | Gilead Sciences, Inc. | $718 | Research payment | Cash or cash equivalent | Vemlidy Drug, HBV | A Phase 2/3 Randomized, Double-Blind Evaluation of the Pharmacokinetics, Safety, and Antiviral Efficacy of Tenofovir Ala | 2019 |
| 2019-12-19 | Novo Nordisk AS | $6,000 | Research payment | Cash or cash equivalent | Sogroya Biological, Growth Hormone | NN8640-4263 | 2019 |
| 2019-12-19 | Novo Nordisk AS | $2,500 | Research payment | Cash or cash equivalent | Sogroya Biological, Growth Hormone | NN8640-4263 | 2019 |
| 2019-12-19 | Novo Nordisk AS | $1,000 | Research payment | Cash or cash equivalent | Sogroya Biological, Growth Hormone | NN8640-4263 | 2019 |
| 2019-12-18 | Gilead Sciences, Inc. | $1,284 | Research payment | Cash or cash equivalent | Epclusa Drug, HCV | A Phase 2, Open-Label, Multicenter, Multi-cohort Study to Investigate the Safety and Efficacy of Sofosbuvir/Velpatasvir | 2019 |
| 2019-12-18 | Gilead Sciences, Inc. | $1,156 | Research payment | Cash or cash equivalent | Vemlidy Drug, HBV | A Phase 2/3 Randomized, Double-Blind Evaluation of the Pharmacokinetics, Safety, and Antiviral Efficacy of Tenofovir Ala | 2019 |
| 2019-12-18 | Travere Therapeutics, Inc. | $715 | Research payment | Cash or cash equivalent | (810) Chenodal Drug, Hepatology | 018CTXX15001 | 2019 |
| 2019-12-18 | Travere Therapeutics, Inc. | $715 | Research payment | Cash or cash equivalent | (810) Chenodal Drug, Hepatology | 018CTXX15001 | 2019 |
| 2019-12-17 | Mallinckrodt Enterprises LLC | $18,469 | Research payment | Cash or cash equivalent | INOMAX Drug, CRITICAL CARE | REGISTRY EVALUATING PREMATURE AND TERM-NEAR-TERM NEONATES WITH PULMONARY HYPERTENSION RECEIVING INHALED NITRIC OXIDE | 2019 |
| 2019-12-13 | Merck Sharp & Dohme LLC | $25,556 | Research payment | Cash or cash equivalent | PRIMAXIN Drug, INFECTIOUS DISEASE | Comparative In Vitro Activity of Imipenem-Relebactam against Pediatric Drug-Resistant Gram Negative Isolates from three | 2019 |
| 2019-12-12 | Astellas Pharma Global Development | $9,412 | Research payment | Cash or cash equivalent | CRESEMBA Drug, INFECTIOUS DISEASES | A Phase 2, Open-Label, Non-Comparative, Multicenter Study to Evaluate the Safety and Tolerability, Efficacy and Pharmaco | 2019 |
| 2019-12-12 | Astellas Pharma Global Development | $200 | Research payment | Cash or cash equivalent | CRESEMBA Drug, INFECTIOUS DISEASES | A Phase 2, Open-Label, Non-Comparative, Multicenter Study to Evaluate the Safety and Tolerability, Efficacy and Pharmaco | 2019 |
| 2019-12-12 | BioMarin Pharmaceutical Inc. | $200 | Research payment | Cash or cash equivalent | Naglazyme Biological, MPS VI | MPS VI Clinical Surveillance Program (CSP) | 2019 |
| 2019-12-05 | Genentech, Inc. | $3,797 | Research payment | Cash or cash equivalent | Non-Covered Product Drug, None | CONFIRMATORY STUDY | 2019 |
| 2019-12-05 | PFIZER INC. | $961 | Research payment | Cash or cash equivalent | PREVNAR - 13 Biological, VACCINES | A PHASE 2 RANDOMIZED OPENLABEL TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A MULTIVALENT PNEUMOCOCCAL CONJUGATE V | 2019 |
| 2019-12-05 | Merck Sharp & Dohme LLC | $500 | Research payment | Cash or cash equivalent | MK-1654 Drug, INFECTIOUS DISEASE | A Double-blind, Randomized, Placebo-controlled, Single Ascending Dose Trial to Evaluate the Safety, Tolerability, and Ph | 2019 |
| 2019-12-03 | Shire North American Group Inc | $881 | Research payment | Cash or cash equivalent | GATTEX Drug, INTERNAL MEDICINE | A RETROSPECTIVE AND PROSPECTIVE, OPEN LABEL, LONG-TERM SAFETY AND EFFICACY STUDY OF TEDUGLUTIDE IN PEDIATRIC PATIENTS WI | 2019 |
| 2019-11-30 | JAZZ PHARMACEUTICALS INC. | $129,816 | Research payment | In-kind items and services | DEFITELIO Drug, HEMATOLOGY | A PHASE 3, RANDOMIZED, ADAPTIVE STUDY COMPARING THE EFFICACY AND SAFETY OF DEFIBROTIDE VS BEST SUPPORTIVE CARE IN THE PR | 2019 |
| 2019-11-29 | Edwards Lifesciences Corporation | $21,174 | Research payment | Cash or cash equivalent | Edwards SAPIEN 3 Transcatheter Heart Valve Device, Transcatheter Heart Valves | COMPASSION S3 2015-01 | 2019 |
| 2019-11-29 | Edwards Lifesciences Corporation | $17,603 | Research payment | Cash or cash equivalent | Edwards SAPIEN 3 Transcatheter Heart Valve Device, Transcatheter Heart Valves | ALTERRA Early Feasibility 2016-04 | 2019 |
| 2019-11-27 | Amgen Inc. | $16,250 | Research payment | Cash or cash equivalent | Aimovig Biological, Neuroscience | Phase P3 Pediatric Study (EM) | 2019 |
| 2019-11-27 | Amgen Inc. | $14,350 | Research payment | Cash or cash equivalent | Aimovig Biological, Neuroscience | Ph3 Pediatric CM Study | 2019 |
| 2019-11-27 | Shire North American Group Inc | $719 | Research payment | Cash or cash equivalent | GATTEX Drug, INTERNAL MEDICINE | A RETROSPECTIVE AND PROSPECTIVE, OPEN LABEL, LONG-TERM SAFETY AND EFFICACY STUDY OF TEDUGLUTIDE IN PEDIATRIC PATIENTS WI | 2019 |
| 2019-11-27 | PFIZER INC. | $500 | Research payment | Cash or cash equivalent | A PHASE 3 MULTICENTER RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED PARALLELGROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY O | 2019 | |
| 2019-11-26 | BioFire Diagnostics, LLC | $6,000 | Research payment | In-kind items and services | SpotFire System Device, Clinical Diagnostics | SpotFire RST Pivotal Study | 2019 |
| 2019-11-25 | Genentech, Inc. | $75 | Research payment | Cash or cash equivalent | Pegasys Biological, Virology & Specialty Care | PEG LAMIVUDINE ENTECAVIR TX IN CHILDREN WITH CHRONIC HBV | 2019 |
| 2019-11-23 | PFIZER INC. | $822 | Research payment | Cash or cash equivalent | PREVNAR - 13 Biological, VACCINES | A PHASE 2 RANDOMIZED OPENLABEL TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A MULTIVALENT PNEUMOCOCCAL CONJUGATE V | 2019 |
| 2019-11-21 | Allergan, Inc. | $7,217 | Research payment | Cash or cash equivalent | DALVANCE Drug, ANTI-INFECTIVE | PHARMACOKINETICS OF A SINGLE-DOSE OF DALBAVANCIN IN PRETERM NEONATES TO INFANTS AGES 3 MONTHS WITH SUSPECTED OR CONFIRME | 2019 |
| 2019-11-21 | Edwards Lifesciences Corporation | $850 | Research payment | Cash or cash equivalent | COMPASSION Study 2006-09 | 2019 | |
| 2019-11-21 | SWEDISH ORPHAN BIOVITRUM AB | $94 | Research payment | Cash or cash equivalent | KINERET Drug, INFLAMMATION | SOBI.ANAKIN-301 | 2019 |
| 2019-11-19 | Shire North American Group Inc | $1,776 | Research payment | Cash or cash equivalent | GATTEX Drug, INTERNAL MEDICINE | A RETROSPECTIVE AND PROSPECTIVE, OPEN LABEL, LONG-TERM SAFETY AND EFFICACY STUDY OF TEDUGLUTIDE IN PEDIATRIC PATIENTS WI | 2019 |
| 2019-11-19 | OXFORD GENE TECHNOLOGY INC | $141 | Food and Beverage (6 payments) | In-kind items and services | 2019 | ||
| 2019-11-18 | BioFire Diagnostics, LLC | $9,306 | Research payment | In-kind items and services | FilmArray System Device, Clinical Diagnostics | FilmArray GI Swab Pivotal Study | 2019 |
| 2019-11-14 | Edwards Lifesciences Corporation | $9,218 | Research payment | Cash or cash equivalent | Edwards SAPIEN 3 Transcatheter Heart Valve Device, Transcatheter Heart Valves | ALTERRA Early Feasibility 2016-04 | 2019 |
| 2019-11-14 | BioFire Diagnostics, LLC | $3,240 | Research payment | In-kind items and services | SpotFire System Device, Clinical Diagnostics | SpotFire RST Pivotal Study | 2019 |
| 2019-11-14 | Edwards Lifesciences Corporation | $854 | Research payment | Cash or cash equivalent | Edwards SAPIEN 3 Transcatheter Heart Valve Device, Transcatheter Heart Valves | COMPASSION S3 2015-01 | 2019 |
| 2019-11-14 | Edwards Lifesciences Corporation | $425 | Research payment | Cash or cash equivalent | COMPASSION Study 2006-09 | 2019 | |
| 2019-11-13 | Gilead Sciences, Inc. | $510 | Research payment | Cash or cash equivalent | Sovaldi Drug, HCV | A Long Term Follow-up Registry for Pediatric Subjects Who Received Treatment in Gilead-Sponsored Chronic Hepatitis C Inf | 2019 |
| 2019-11-12 | Amgen Inc. | $777 | Research payment | In-kind items and services | Parsabiv Biological, Nephrology | AMG 416 Pediatric | 2019 |
| 2019-11-09 | BioFire Diagnostics, LLC | $10,555 | Research payment | Cash or cash equivalent | FilmArray System Device, Clinical Diagnostics | FilmArray GI Swab Pivotal Study | 2019 |
| 2019-11-08 | BioFire Diagnostics, LLC | $19,195 | Research payment | Cash or cash equivalent | SpotFire System Device, Clinical Diagnostics | FilmArray 804 Pilot Study | 2019 |
| 2019-11-07 | BioFire Diagnostics, LLC | $40,500 | Research payment | In-kind items and services | SpotFire System Device, Clinical Diagnostics | FilmArray 804 Pilot Study | 2019 |
| 2019-11-07 | Merck Sharp & Dohme LLC | $450 | Research payment | Cash or cash equivalent | MK-1654 Drug, INFECTIOUS DISEASE | A Double-blind, Randomized, Placebo-controlled, Single Ascending Dose Trial to Evaluate the Safety, Tolerability, and Ph | 2019 |
| 2019-11-07 | BioFire Diagnostics, LLC | $40 | Research payment | Cash or cash equivalent | FilmArray System Device, Clinical Diagnostics | FilmArray GI Swab Pivotal Study | 2019 |
| 2019-11-04 | Alexion Pharmaceuticals, Inc. | $863 | Research payment | Cash or cash equivalent | Strensiq Drug, Endocrinology | An Observational, Longitudinal, Prospective, Long-Term Registry Of Patients With Hypophosphatasia HPP | 2019 |
| 2019-11-04 | Alexion Pharmaceuticals, Inc. | $863 | Research payment | Cash or cash equivalent | Strensiq Drug, Endocrinology | An Observational, Longitudinal, Prospective, Long-Term Registry Of Patients With Hypophosphatasia HPP | 2019 |
| 2019-11-04 | Alexion Pharmaceuticals, Inc. | $863 | Research payment | Cash or cash equivalent | Strensiq Drug, Endocrinology | An Observational, Longitudinal, Prospective, Long-Term Registry Of Patients With Hypophosphatasia HPP | 2019 |
| 2019-11-04 | Alexion Pharmaceuticals, Inc. | $863 | Research payment | Cash or cash equivalent | Strensiq Drug, Endocrinology | An Observational, Longitudinal, Prospective, Long-Term Registry Of Patients With Hypophosphatasia HPP | 2019 |
| 2019-10-31 | BioFire Diagnostics, LLC | $13,500 | Research payment | In-kind items and services | FilmArray System Device, Clinical Diagnostics | FilmArray GI Swab Pivotal Study | 2019 |
| 2019-10-29 | Shire North American Group Inc | $411 | Research payment | Cash or cash equivalent | GATTEX Drug, INTERNAL MEDICINE | A RETROSPECTIVE AND PROSPECTIVE, OPEN LABEL, LONG-TERM SAFETY AND EFFICACY STUDY OF TEDUGLUTIDE IN PEDIATRIC PATIENTS WI | 2019 |
| 2019-10-28 | BioFire Diagnostics, LLC | $39,260 | Research payment | Cash or cash equivalent | SpotFire System Device, Clinical Diagnostics | FilmArray 804 Pilot Study | 2019 |
| 2019-10-28 | Merck Sharp & Dohme LLC | $329 | Research payment | In-kind items and services | MK-1654 Drug, INFECTIOUS DISEASE | A Double-blind, Randomized, Placebo-controlled, Single Ascending Dose Trial to Evaluate the Safety, Tolerability, and Ph | 2019 |
| 2019-10-24 | Amgen Inc. | $20,630 | Research payment | Cash or cash equivalent | Parsabiv Biological, Nephrology | Pediatric Multi-Dose | 2019 |
| 2019-10-24 | PFIZER INC. | $961 | Research payment | Cash or cash equivalent | PREVNAR - 13 Biological, VACCINES | A PHASE 2 RANDOMIZED OPENLABEL TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A MULTIVALENT PNEUMOCOCCAL CONJUGATE V | 2019 |
| 2019-10-23 | Gilead Sciences, Inc. | $1,612 | Research payment | Cash or cash equivalent | Sovaldi Drug, HCV | A Long Term Follow-up Registry for Pediatric Subjects Who Received Treatment in Gilead-Sponsored Chronic Hepatitis C Inf | 2019 |
| 2019-10-23 | Gilead Sciences, Inc. | $996 | Research payment | Cash or cash equivalent | Vemlidy Drug, HBV | A Phase 2/3 Randomized, Double-Blind Evaluation of the Pharmacokinetics, Safety, and Antiviral Efficacy of Tenofovir Ala | 2019 |
| 2019-10-23 | Gilead Sciences, Inc. | $958 | Research payment | Cash or cash equivalent | Epclusa Drug, HCV | A Phase 2, Open-Label, Multicenter, Multi-cohort Study to Investigate the Safety and Efficacy of Sofosbuvir/Velpatasvir | 2019 |
| 2019-10-22 | Amgen Inc. | $1,689 | Research payment | In-kind items and services | Parsabiv Biological, Nephrology | Pediatric Multi-Dose | 2019 |
| 2019-10-21 | SWEDISH ORPHAN BIOVITRUM AB | $1,556 | Research payment | Cash or cash equivalent | KINERET Drug, INFLAMMATION | SOBI.ANAKIN-301 | 2019 |
| 2019-10-21 | Travere Therapeutics, Inc. | $1,498 | Research payment | Cash or cash equivalent | DUET | 2019 | |
| 2019-10-21 | Travere Therapeutics, Inc. | $148 | Research payment | Cash or cash equivalent | DUET | 2019 | |
| 2019-10-17 | Shire North American Group Inc | $936 | Research payment | Cash or cash equivalent | GATTEX Drug, INTERNAL MEDICINE | A RETROSPECTIVE AND PROSPECTIVE, OPEN LABEL, LONG-TERM SAFETY AND EFFICACY STUDY OF TEDUGLUTIDE IN PEDIATRIC PATIENTS WI | 2019 |
| 2019-10-15 | Allergan, Inc. | $500 | Research payment | Cash or cash equivalent | LINZESS Drug, GASTROENTEROLOGY | A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, SAFETY AND EFFIACY STUDY OF A RANGE OF LINA | 2019 |
| 2019-10-14 | Travere Therapeutics, Inc. | $200 | Research payment | Cash or cash equivalent | 021FSGS16010 | 2019 | |
| 2019-10-14 | BioFire Diagnostics, LLC | $151 | Research payment | Cash or cash equivalent | FilmArray System Device, Clinical Diagnostics | FilmArray GI Swab Pivotal Study | 2019 |
| 2019-10-11 | BioFire Diagnostics, LLC | $17,125 | Research payment | Cash or cash equivalent | FilmArray System Device, Clinical Diagnostics | FilmArray GI Swab Pivotal Study | 2019 |
| 2019-10-10 | SANOFI PASTEUR INC. | $12,880 | Research payment | Cash or cash equivalent | YELLOW FEVER Drug | STA00011 Stamaril Yellow Fever | 2019 |
| 2019-10-10 | SANOFI US SERVICES INC. | $4,500 | Research payment | Cash or cash equivalent | DUPIXENT Drug, IMMUNOLOGY | Evaluation of Biomarkers of Atopic Dermatitis in Pediatric Patients Whose Disease is Not Adequately Controlled With Topi | 2019 |
| 2019-10-10 | Shire North American Group Inc | $2,157 | Research payment | Cash or cash equivalent | GATTEX Drug, INTERNAL MEDICINE | A RETROSPECTIVE AND PROSPECTIVE, OPEN LABEL, LONG-TERM SAFETY AND EFFICACY STUDY OF TEDUGLUTIDE IN PEDIATRIC PATIENTS WI | 2019 |
| 2019-10-10 | SANOFI US SERVICES INC. | $1,750 | Research payment | Cash or cash equivalent | DUPIXENT Drug, IMMUNOLOGY | Evaluation of Biomarkers of Atopic Dermatitis in Pediatric Patients Whose Disease is Not Adequately Controlled With Topi | 2019 |
| 2019-10-10 | Grifols Therapeutics LLC | $1,000 | Research payment | Cash or cash equivalent | Alphanate Biological, Hematology | A Multicenter Phase 2 Open-Label, Single-Arm, Prospective, Interventional Study of PlasmaDerived Factor VIIIVWF Alphanat | 2019 |
| 2019-10-10 | Allergan, Inc. | $300 | Research payment | Cash or cash equivalent | DALVANCE Drug, ANTI-INFECTIVE | PHARMACOKINETICS OF A SINGLE-DOSE OF DALBAVANCIN IN PRETERM NEONATES TO INFANTS AGES 3 MONTHS WITH SUSPECTED OR CONFIRME | 2019 |
| 2019-10-08 | BioFire Diagnostics, LLC | $1,663 | Research payment | In-kind items and services | SpotFire System Device, Clinical Diagnostics | FilmArray 804 Pilot Study | 2019 |
| 2019-10-08 | Incyte Corporation | $74 | Research payment | Cash or cash equivalent | A Phase 2 Study of the JAK1, JAK2 Inhibitor Ruxolitinib With Chemotherapy in Children With De Novo High Risk CRLF2 Rearr | 2019 | |
| 2019-10-08 | Incyte Corporation | $21 | Research payment | Cash or cash equivalent | A Phase 2 Study of the JAK1, JAK2 Inhibitor Ruxolitinib With Chemotherapy in Children With De Novo High Risk CRLF2 Rearr | 2019 | |
| 2019-10-08 | Incyte Corporation | $12 | Research payment | Cash or cash equivalent | A Phase 2 Study of the JAK1, JAK2 Inhibitor Ruxolitinib With Chemotherapy in Children With De Novo High Risk CRLF2 Rearr | 2019 | |
| 2019-10-08 | Incyte Corporation | $12 | Research payment | Cash or cash equivalent | A Phase 2 Study of the JAK1, JAK2 Inhibitor Ruxolitinib With Chemotherapy in Children With De Novo High Risk CRLF2 Rearr | 2019 | |
| 2019-10-08 | BioFire Diagnostics, LLC | $3 | Research payment | Cash or cash equivalent | FilmArray System Device, Clinical Diagnostics | FilmArray GI Swab Pivotal Study | 2019 |
| 2019-10-05 | Astellas US Technologies | $315 | Research payment | In-kind items and services | CRESEMBA Drug, INFECTIOUS DISEASES | A Phase 2, Open-Label, Non-Comparative, Multicenter Study to Evaluate the Safety, Efficacy and Pharmacokinetics of Isavu | 2019 |
| 2019-10-05 | Astellas US Technologies | $315 | Research payment | In-kind items and services | CRESEMBA Drug, INFECTIOUS DISEASES | A Phase 2, Open-Label, Non-Comparative, Multicenter Study to Evaluate the Safety, Efficacy and Pharmacokinetics of Isavu | 2019 |
| 2019-10-05 | Astellas US Technologies | $315 | Research payment | In-kind items and services | CRESEMBA Drug, INFECTIOUS DISEASES | A Phase 2, Open-Label, Non-Comparative, Multicenter Study to Evaluate the Safety, Efficacy and Pharmacokinetics of Isavu | 2019 |
| 2019-10-05 | Astellas US Technologies | $315 | Research payment | In-kind items and services | CRESEMBA Drug, INFECTIOUS DISEASES | A Phase 2, Open-Label, Non-Comparative, Multicenter Study to Evaluate the Safety, Efficacy and Pharmacokinetics of Isavu | 2019 |
| 2019-10-05 | Astellas US Technologies | $315 | Research payment | In-kind items and services | CRESEMBA Drug, INFECTIOUS DISEASES | A Phase 2, Open-Label, Non-Comparative, Multicenter Study to Evaluate the Safety, Efficacy and Pharmacokinetics of Isavu | 2019 |
| 2019-10-05 | Astellas US Technologies | $315 | Research payment | In-kind items and services | CRESEMBA Drug, INFECTIOUS DISEASES | A Phase 2, Open-Label, Non-Comparative, Multicenter Study to Evaluate the Safety, Efficacy and Pharmacokinetics of Isavu | 2019 |
| 2019-10-04 | Mallinckrodt Enterprises LLC | $10,294 | Research payment | Cash or cash equivalent | INOMAX Drug, CRITICAL CARE | REGISTRY EVALUATING PREMATURE AND TERM-NEAR-TERM NEONATES WITH PULMONARY HYPERTENSION RECEIVING INHALED NITRIC OXIDE | 2019 |
| 2019-10-04 | Philips North America LLC | $1,000 | Research payment | Cash or cash equivalent | US Und Device, Cardiology/Vascular Diseases | VM 5.0 | 2019 |
| 2019-10-04 | GENZYME CORPORATION | $700 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | CERDELGA Drug, RARE DISEASE GENETICS | 2019 | |
| 2019-10-04 | Novartis Pharmaceuticals Corporation | $600 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | KYMRIAH Biological, ONCOLOGY | 2019 | |
| 2019-10-03 | Alexion Pharmaceuticals, Inc. | $600 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | Kanuma Drug, Immunology | 2019 | |
| 2019-10-02 | Genentech, Inc. | $7,388 | Research payment | Cash or cash equivalent | Pegasys Biological, Virology & Specialty Care | PEG LAMIVUDINE ENTECAVIR TX IN CHILDREN WITH CHRONIC HBV | 2019 |
| 2019-09-30 | BioFire Diagnostics, LLC | $39,000 | Research payment | In-kind items and services | FilmArray System Device, Clinical Diagnostics | FilmArray GI Swab Pivotal Study | 2019 |
| 2019-09-30 | BioFire Diagnostics, LLC | $1,429 | Research payment | In-kind items and services | SpotFire System Device, Clinical Diagnostics | FilmArray 804 Pilot Study | 2019 |
| 2019-09-30 | BioFire Diagnostics, LLC | $1,429 | Research payment | In-kind items and services | SpotFire System Device, Clinical Diagnostics | FilmArray 804 Pilot Study | 2019 |
| 2019-09-30 | BioFire Diagnostics, LLC | $232 | Research payment | In-kind items and services | FilmArray System Device, Clinical Diagnostics | FilmArray GI Swab Pivotal Study | 2019 |
| 2019-09-30 | Merck Sharp & Dohme LLC | $1 | Research payment | In-kind items and services | MK-1654 Drug, INFECTIOUS DISEASE | A Double-blind, Randomized, Placebo-controlled, Single Ascending Dose Trial to Evaluate the Safety, Tolerability, and Ph | 2019 |
| 2019-09-26 | GlaxoSmithKline, LLC. | $1,500 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | MENVEO Biological, VACCINES | 2019 | |
| 2019-09-26 | Genentech, Inc. | $828 | Research payment | Cash or cash equivalent | Pegasys Biological, Virology & Specialty Care | PEG LAMIVUDINE ENTECAVIR TX IN CHILDREN WITH CHRONIC HBV | 2019 |
| 2019-09-24 | PFIZER INC. | $1,339 | Research payment | Cash or cash equivalent | PREVNAR - 13 Biological, VACCINES | A PHASE 2 RANDOMIZED OPENLABEL TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A MULTIVALENT PNEUMOCOCCAL CONJUGATE V | 2019 |
| 2019-09-19 | Edwards Lifesciences Corporation | $22,703 | Research payment | Cash or cash equivalent | Edwards SAPIEN 3 Transcatheter Heart Valve Device, Transcatheter Heart Valves | ALTERRA Early Feasibility 2016-04 | 2019 |
| 2019-09-19 | Edwards Lifesciences Corporation | $569 | Research payment | Cash or cash equivalent | Edwards SAPIEN 3 Transcatheter Heart Valve Device, Transcatheter Heart Valves | COMPASSION S3 2015-01 | 2019 |
| 2019-09-19 | Mallinckrodt Enterprises LLC | $300 | Research payment | Cash or cash equivalent | INOMAX Drug, CRITICAL CARE | REGISTRY EVALUATING PREMATURE AND TERM-NEAR-TERM NEONATES WITH PULMONARY HYPERTENSION RECEIVING INHALED NITRIC OXIDE | 2019 |
| 2019-09-18 | Astellas Pharma Global Development | $58,865 | Research payment | Cash or cash equivalent | CRESEMBA Drug, INFECTIOUS DISEASES | Observational Disease Registry of Patients Treated With Systemic Mold-Active Triazoles | 2019 |
| 2019-09-18 | BioFire Diagnostics, LLC | $11,740 | Research payment | Cash or cash equivalent | FilmArray System Device, Clinical Diagnostics | FilmArray GI Swab Pivotal Study | 2019 |
| 2019-09-18 | Gilead Sciences, Inc. | $1,802 | Research payment | Cash or cash equivalent | Vemlidy Drug, HBV | A Phase 2/3 Randomized, Double-Blind Evaluation of the Pharmacokinetics, Safety, and Antiviral Efficacy of Tenofovir Ala | 2019 |
| 2019-09-18 | SOBI, INC | $1,500 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | SYNAGIS Drug, Immunology | 2019 | |
| 2019-09-18 | SANOFI PASTEUR INC. | $1,500 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | PENTACEL Drug, VACCINES | 2019 | |
| 2019-09-17 | Shire North American Group Inc | $2,092 | Research payment | Cash or cash equivalent | GATTEX Drug, INTERNAL MEDICINE | A RETROSPECTIVE AND PROSPECTIVE, OPEN LABEL, LONG-TERM SAFETY AND EFFICACY STUDY OF TEDUGLUTIDE IN PEDIATRIC PATIENTS WI | 2019 |
| 2019-09-17 | Shire North American Group Inc | $1,676 | Research payment | Cash or cash equivalent | GATTEX Drug, INTERNAL MEDICINE | A RETROSPECTIVE AND PROSPECTIVE, OPEN LABEL, LONG-TERM SAFETY AND EFFICACY STUDY OF TEDUGLUTIDE IN PEDIATRIC PATIENTS WI | 2019 |
| 2019-09-16 | Genentech, Inc. | $5,134 | Research payment | Cash or cash equivalent | Non-Covered Product Drug, None | CONFIRMATORY STUDY | 2019 |
| 2019-09-12 | PFIZER INC. | $1,000 | Research payment | Cash or cash equivalent | A PHASE 3 MULTICENTER RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED PARALLELGROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY O | 2019 | |
| 2019-09-12 | Allergan, Inc. | $500 | Education | Cash or cash equivalent | 2019 | ||
| 2019-09-11 | VERTEX PHARMACEUTICALS INCORPORATED | $18,511 | Research payment | Cash or cash equivalent | A Study Evaluating the Long-term Safety of VX-445 Combination Therapy | 2019 | |
| 2019-09-11 | BioFire Diagnostics, LLC | $8,499 | Research payment | Cash or cash equivalent | FilmArray System Device, Clinical Diagnostics | FilmArray CSI Pilot Study | 2019 |
| 2019-09-11 | Edwards Lifesciences Corporation | $8,423 | Research payment | Cash or cash equivalent | Edwards SAPIEN 3 Transcatheter Heart Valve Device, Transcatheter Heart Valves | ALTERRA Early Feasibility 2016-04 | 2019 |
| 2019-09-11 | BioMarin Pharmaceutical Inc. | $3,800 | Research payment | Cash or cash equivalent | Kuvan Drug, PKU | PKU Demographics, Outcomes, and Safety Registry | 2019 |
| 2019-09-11 | Edwards Lifesciences Corporation | $3,324 | Research payment | Cash or cash equivalent | Edwards SAPIEN 3 Transcatheter Heart Valve Device, Transcatheter Heart Valves | COMPASSION S3 2015-01 | 2019 |
| 2019-09-10 | Shire North American Group Inc | $2,723 | Research payment | Cash or cash equivalent | GATTEX Drug, INTERNAL MEDICINE | A RETROSPECTIVE AND PROSPECTIVE, OPEN LABEL, LONG-TERM SAFETY AND EFFICACY STUDY OF TEDUGLUTIDE IN PEDIATRIC PATIENTS WI | 2019 |
| 2019-09-10 | Shire North American Group Inc | $1,797 | Research payment | Cash or cash equivalent | GATTEX Drug, INTERNAL MEDICINE | A RETROSPECTIVE AND PROSPECTIVE, OPEN LABEL, LONG-TERM SAFETY AND EFFICACY STUDY OF TEDUGLUTIDE IN PEDIATRIC PATIENTS WI | 2019 |
| 2019-09-10 | Shire North American Group Inc | $1,332 | Research payment | Cash or cash equivalent | GATTEX Drug, INTERNAL MEDICINE | A RETROSPECTIVE AND PROSPECTIVE, OPEN LABEL, LONG-TERM SAFETY AND EFFICACY STUDY OF TEDUGLUTIDE IN PEDIATRIC PATIENTS WI | 2019 |
| 2019-09-10 | Allergan, Inc. | $931 | Research payment | Cash or cash equivalent | LINZESS Drug, GASTROENTEROLOGY | A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Safety and Efficacy Study of a Range of Lin | 2019 |
| 2019-09-10 | Shire North American Group Inc | $855 | Research payment | Cash or cash equivalent | GATTEX Drug, INTERNAL MEDICINE | A RETROSPECTIVE AND PROSPECTIVE, OPEN LABEL, LONG-TERM SAFETY AND EFFICACY STUDY OF TEDUGLUTIDE IN PEDIATRIC PATIENTS WI | 2019 |
| 2019-09-10 | Shire North American Group Inc | $805 | Research payment | Cash or cash equivalent | GATTEX Drug, INTERNAL MEDICINE | A RETROSPECTIVE AND PROSPECTIVE, OPEN LABEL, LONG-TERM SAFETY AND EFFICACY STUDY OF TEDUGLUTIDE IN PEDIATRIC PATIENTS WI | 2019 |
| 2019-09-09 | Merck Sharp & Dohme LLC | $25,556 | Research payment | Cash or cash equivalent | PRIMAXIN Drug, INFECTIOUS DISEASE | Comparative In Vitro Activity of Imipenem-Relebactam against Pediatric Drug-Resistant Gram Negative Isolates from three | 2019 |
| 2019-09-09 | BioFire Diagnostics, LLC | $9,300 | Research payment | In-kind items and services | FilmArray System Device, Clinical Diagnostics | FilmArray GI Swab Pivotal Study | 2019 |
| 2019-09-09 | Gilead Sciences, Inc. | $15 | Research payment | Cash or cash equivalent | Sovaldi Drug, HCV | A Long Term Follow-up Registry for Pediatric Subjects Who Received Treatment in Gilead-Sponsored Chronic Hepatitis C Inf | 2019 |
| 2019-09-05 | JAZZ PHARMACEUTICALS INC. | $237,499 | Research payment | Cash or cash equivalent | DEFITELIO Drug, HEMATOLOGY | USING ULTRASOUND ELASTOGRAPHY TO PREDICT DEVELOPMENT OF HEPATIC VENO-OCCLUSIVE DISEASE/SUNISOIDAL OBSTRUCTION SYNDROME. | 2019 |
| 2019-09-05 | Alexion Pharmaceuticals, Inc. | $1,500 | Research payment | Cash or cash equivalent | Strensiq Drug, Endocrinology | An Observational, Longitudinal, Prospective, Long-Term Registry Of Patients With Hypophosphatasia HPP | 2019 |
| 2019-09-05 | SOBI, INC | $1,000 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | SYNAGIS Drug, Immunology | 2019 | |
| 2019-09-05 | BioFire Diagnostics, LLC | $181 | Research payment | In-kind items and services | SpotFire System Device, Clinical Diagnostics | FilmArray 804 Pilot Study | 2019 |
| 2019-09-04 | Novo Nordisk AS | $10,000 | Research payment | In-kind items and services | Sogroya Biological, Growth Hormone | NN8640-4263 | 2019 |
| 2019-09-04 | Abbott Laboratories | $1,500 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | Cardiovascular- Research only Device, Cardiac Arrhythmias and Heart Failure | 2019 | |
| 2019-09-04 | Abbott Laboratories | $1,500 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | Cardiovascular- Research only Device, Cardiac Arrhythmias and Heart Failure | 2019 | |
| 2019-09-04 | Novo Nordisk AS | $831 | Research payment | In-kind items and services | Sogroya Biological, Growth Hormone | NN8640-4263 | 2019 |
| 2019-09-04 | Novo Nordisk AS | $250 | Research payment | In-kind items and services | Sogroya Biological, Growth Hormone | NN8640-4263 | 2019 |
| 2019-09-04 | Novo Nordisk AS | $250 | Research payment | In-kind items and services | Sogroya Biological, Growth Hormone | NN8640-4263 | 2019 |
| 2019-09-04 | Novo Nordisk AS | $150 | Research payment | In-kind items and services | Sogroya Biological, Growth Hormone | NN8640-4263 | 2019 |
| 2019-09-04 | Novo Nordisk AS | $22 | Research payment | In-kind items and services | Sogroya Biological, Growth Hormone | NN8640-4263 | 2019 |
| 2019-09-04 | Novo Nordisk AS | $10 | Research payment | In-kind items and services | Sogroya Biological, Growth Hormone | NN8640-4263 | 2019 |
| 2019-09-04 | Novo Nordisk AS | $9 | Research payment | In-kind items and services | Sogroya Biological, Growth Hormone | NN8640-4263 | 2019 |
| 2019-09-04 | Novo Nordisk AS | $6 | Research payment | In-kind items and services | Sogroya Biological, Growth Hormone | NN8640-4263 | 2019 |
| 2019-09-04 | Novo Nordisk AS | $3 | Research payment | In-kind items and services | Sogroya Biological, Growth Hormone | NN8640-4263 | 2019 |
| 2019-09-04 | Novo Nordisk AS | $1 | Research payment | In-kind items and services | Sogroya Biological, Growth Hormone | NN8640-4263 | 2019 |
| 2019-09-04 | Novo Nordisk AS | $1 | Research payment | In-kind items and services | Sogroya Biological, Growth Hormone | NN8640-4263 | 2019 |
| 2019-09-03 | GE HEALTHCARE | $1,500 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | Device, ULTRASOUND | 2019 | |
| 2019-08-30 | PFIZER INC. | $1,695 | Research payment | Cash or cash equivalent | PREVNAR - 13 Biological, VACCINES | A PHASE 2 RANDOMIZED OPENLABEL TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A MULTIVALENT PNEUMOCOCCAL CONJUGATE V | 2019 |
| 2019-08-29 | Incyte Corporation | $3,000 | Research payment | Cash or cash equivalent | A Phase 2 Study of the JAK1, JAK2 Inhibitor Ruxolitinib With Chemotherapy in Children With De Novo High Risk CRLF2 Rearr | 2019 | |
| 2019-08-29 | Incyte Corporation | $2,000 | Research payment | Cash or cash equivalent | A Phase 2 Study of the JAK1, JAK2 Inhibitor Ruxolitinib With Chemotherapy in Children With De Novo High Risk CRLF2 Rearr | 2019 | |
| 2019-08-29 | BioFire Diagnostics, LLC | $67 | Research payment | In-kind items and services | FilmArray System Device, Clinical Diagnostics | FilmArray GI Swab Pivotal Study | 2019 |
| 2019-08-28 | United Therapeutics Corporation | $400 | Research payment | Cash or cash equivalent | REMODULIN Drug, PAH | INTRAVENOUS REMODULIN TREPROSTINIL AS ADD-ON THERAPY FOR THE TREATMENT OF PERSISTENT PULMONARY HYPERTENSION OF THE NEWBO | 2019 |
| 2019-08-28 | Novo Nordisk AS | $117 | Research payment | In-kind items and services | Sogroya Biological, Growth Hormone | NN8640-4263 | 2019 |
| 2019-08-28 | Novo Nordisk AS | $75 | Research payment | In-kind items and services | Sogroya Biological, Growth Hormone | NN8640-4263 | 2019 |
| 2019-08-27 | Amgen Inc. | $5,174 | Research payment | In-kind items and services | Aimovig Biological, Neuroscience | Phase P3 Pediatric Study (EM) | 2019 |
| 2019-08-27 | BioFire Diagnostics, LLC | $4,650 | Research payment | In-kind items and services | FilmArray System Device, Clinical Diagnostics | FilmArray GI Swab Pivotal Study | 2019 |
| 2019-08-27 | BioFire Diagnostics, LLC | $1,470 | Research payment | In-kind items and services | SpotFire System Device, Clinical Diagnostics | FilmArray 804 Pilot Study | 2019 |
| 2019-08-26 | BioFire Diagnostics, LLC | $288 | Research payment | In-kind items and services | FilmArray System Device, Clinical Diagnostics | FilmArray GI Swab Pivotal Study | 2019 |
| 2019-08-26 | Gilead Sciences, Inc. | $15 | Research payment | Cash or cash equivalent | Sovaldi Drug, HCV | A Long Term Follow-up Registry for Pediatric Subjects Who Received Treatment in Gilead-Sponsored Chronic Hepatitis C Inf | 2019 |
| 2019-08-23 | Edwards Lifesciences Corporation | $5,874 | Research payment | Cash or cash equivalent | Edwards SAPIEN 3 Transcatheter Heart Valve Device, Transcatheter Heart Valves | COMPASSION S3 2015-01 | 2019 |
| 2019-08-23 | Edwards Lifesciences Corporation | $3,833 | Research payment | Cash or cash equivalent | Edwards SAPIEN 3 Transcatheter Heart Valve Device, Transcatheter Heart Valves | ALTERRA Early Feasibility 2016-04 | 2019 |
| 2019-08-21 | Gilead Sciences, Inc. | $903 | Research payment | Cash or cash equivalent | Epclusa Drug, HCV | A Phase 2, Open-Label, Multicenter, Multi-cohort Study to Investigate the Safety and Efficacy of Sofosbuvir/Velpatasvir | 2019 |
| 2019-08-21 | Oticon Medical, LLC | $306 | Education | Cash or cash equivalent | PONTO BONE ANCHORED HEARING SYSTEM Device, Medical Device | 2019 | |
| 2019-08-21 | AMAG Pharmaceuticals, Inc. | $300 | Research payment | Cash or cash equivalent | FERAHEME Drug, PARENTERAL IRON REPLACEMENT | A PHASE 3, RANDOMIZED, OPEN-LABEL, MULTICENTER STUDY TO EVALUATE THE SAFETY COMPARED TO IRON SUCROSE, EFFICACY AND PHARM | 2019 |
| 2019-08-19 | BioFire Diagnostics, LLC | $22,520 | Research payment | Cash or cash equivalent | SpotFire System Device, Clinical Diagnostics | FilmArray 804 Pilot Study | 2019 |
| 2019-08-19 | BioFire Diagnostics, LLC | $1,429 | Research payment | In-kind items and services | SpotFire System Device, Clinical Diagnostics | FilmArray 804 Pilot Study | 2019 |
| 2019-08-16 | ABBVIE INC. | $15,350 | Research payment | Cash or cash equivalent | Lupron Depot Drug, Endocrinology | M16-904 | 2019 |
| 2019-08-16 | BioFire Diagnostics, LLC | $4,232 | Research payment | Cash or cash equivalent | FilmArray System Device, Clinical Diagnostics | FilmArray GI Swab Pivotal Study | 2019 |
| 2019-08-14 | BioFire Diagnostics, LLC | $22,800 | Research payment | In-kind items and services | SpotFire System Device, Clinical Diagnostics | FilmArray 804 Pilot Study | 2019 |
| 2019-08-14 | BioFire Diagnostics, LLC | $9,411 | Research payment | In-kind items and services | FilmArray System Device, Clinical Diagnostics | FilmArray GI Swab Pivotal Study | 2019 |
| 2019-08-14 | United Therapeutics Corporation | $500 | Research payment | Cash or cash equivalent | REMODULIN Drug, PAH | INTRAVENOUS REMODULIN TREPROSTINIL AS ADD-ON THERAPY FOR THE TREATMENT OF PERSISTENT PULMONARY HYPERTENSION OF THE NEWBO | 2019 |
| 2019-08-13 | Eisai Inc. | $1,255 | Research payment | Cash or cash equivalent | Fycompa Drug, Neurology | A Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial With an Open-Label Extension Phase of Perampanel as Ad | 2019 |
| 2019-08-13 | BioFire Diagnostics, LLC | $29 | Research payment | In-kind items and services | SpotFire System Device, Clinical Diagnostics | FilmArray 804 Pilot Study | 2019 |
| 2019-08-12 | Gilead Sciences, Inc. | $1,436 | Research payment | Cash or cash equivalent | Vemlidy Drug, HBV | A Phase 2/3 Randomized, Double-Blind Evaluation of the Pharmacokinetics, Safety, and Antiviral Efficacy of Tenofovir Ala | 2019 |
| 2019-08-12 | Gilead Sciences, Inc. | $1,300 | Research payment | Cash or cash equivalent | Vemlidy Drug, HBV | A Phase 2/3 Randomized, Double-Blind Evaluation of the Pharmacokinetics, Safety, and Antiviral Efficacy of Tenofovir Ala | 2019 |
| 2019-08-12 | ZOLL Medical Corporation | $500 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | Device, DEFIBRILLATOR | 2019 | |
| 2019-08-12 | BioFire Diagnostics, LLC | $15 | Research payment | In-kind items and services | SpotFire System Device, Clinical Diagnostics | FilmArray 804 Pilot Study | 2019 |
| 2019-08-09 | PFIZER INC. | $1,500 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | EUCRISA Drug, DERMATOLOGY | 2019 | |
| 2019-08-08 | Amgen Inc. | $261 | Research payment | In-kind items and services | Aimovig Biological, Neuroscience | Phase P3 Pediatric Study (EM) | 2019 |
| 2019-08-08 | Amgen Inc. | $138 | Research payment | In-kind items and services | Aimovig Biological, Neuroscience | Ph3 Pediatric CM Study | 2019 |
| 2019-08-07 | Astellas Pharma Global Development | $1,000 | Research payment | Cash or cash equivalent | CRESEMBA Drug, INFECTIOUS DISEASES | A Phase 1, Open-label, Multicenter, Non-comparative Pharmacokinetics and Safety Study of Intravenous and Oral Isavuconaz | 2019 |
| 2019-08-06 | PFIZER INC. | $961 | Research payment | Cash or cash equivalent | PREVNAR - 13 Biological, VACCINES | A PHASE 2 RANDOMIZED OPENLABEL TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A MULTIVALENT PNEUMOCOCCAL CONJUGATE V | 2019 |
| 2019-08-02 | Edwards Lifesciences Corporation | $10,974 | Research payment | Cash or cash equivalent | Edwards SAPIEN 3 Transcatheter Heart Valve Device, Transcatheter Heart Valves | COMPASSION S3 2015-01 | 2019 |
| 2019-08-02 | Edwards Lifesciences Corporation | $7,383 | Research payment | Cash or cash equivalent | Edwards SAPIEN 3 Transcatheter Heart Valve Device, Transcatheter Heart Valves | ALTERRA Early Feasibility 2016-04 | 2019 |
| 2019-08-01 | BioFire Diagnostics, LLC | $39,587 | Research payment | Cash or cash equivalent | FilmArray System Device, Clinical Diagnostics | FilmArray CSI Pilot Study | 2019 |
| 2019-08-01 | Genentech, Inc. | $815 | Research payment | Cash or cash equivalent | Pegasys Biological, Virology & Specialty Care | PEG LAMIVUDINE ENTECAVIR TX IN CHILDREN WITH CHRONIC HBV | 2019 |
| 2019-07-30 | Eisai Inc. | $300 | Research payment | Cash or cash equivalent | Fycompa Drug, Neurology | An Open-Label, Multicenter Study With an Extension Phase to Evaluate the Safety, Tolerability, and Exposure-Efficacy Rel | 2019 |
| 2019-07-29 | Purdue Pharma L.P. | $10,200 | Research payment | Cash or cash equivalent | OXYCONTIN Drug, PAIN MANAGEMENT | PMR 2923-2 study of OxyContin utilization among pediatric patients | 2019 |
| 2019-07-27 | Allergan, Inc. | $500 | Education | Cash or cash equivalent | 2019 | ||
| 2019-07-25 | Mylan Specialty L.P. | $500 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | TOBI Drug, Respiratory and Allergy | 2019 | |
| 2019-07-23 | Genentech, Inc. | $8,500 | Research payment | Cash or cash equivalent | HEMLIBRA Biological, Hematology | EMICIZUMAB MINOR SURGERY | 2019 |
The latest 200 records of 465.
CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.
The area Census
County outline, the place (blue), the tract (orange) and the ZIP center (dot).
In Kansas City, MO, county Jackson County, MO, state Missouri; placed by its city name.
| Measure | Place (city or town) Kansas City, MO | County Jackson County, MO | State Missouri |
|---|---|---|---|
| Population B01003 | 510,612 | 719,976 | 6,191,814 |
| Population, 2020 census P1 | 508,090 | 717,204 | 6,154,913 |
| Median age B01002 | 35.8 | 37.0 | 39.0 |
| Under 18 B01001 | 22.5% | 23.3% | 22.3% |
| 65 and over B01001 | 14.3% | 15.9% | 17.9% |
| Households B11001 | 221,979 | 306,798 | 2,508,227 |
| Foreign born B05002 | 8.6% | 6.6% | 4.5% |
| Median household income B19013 | $69,166 | $68,577 | $70,702 |
| Median family income B19113 | $92,934 | $90,585 | $91,360 |
| Per capita income B19301 | $41,393 | $39,559 | $39,695 |
| Poverty rate B17001 | 14.6% | 14.1% | 12.6% |
| Unemployment rate B23025 | 4.4% | 4.7% | 4.0% |
| Civilian labor force B23025 | 279,828 | 381,433 | 3,120,639 |
| Mean commute (minutes) B08013 | 21.7 | 23.4 | 23.5 |
| Bachelor's degree or higher B15003 | 38.4% | 34.0% | 32.4% |
| Housing units B25001 | 245,346 | 336,288 | 2,825,287 |
| Owner-occupied B25003 | 55.4% | 59.1% | 68.1% |
| Renters B25003 | 44.6% | 40.9% | 31.9% |
| Median home value B25077 | $242,900 | $230,500 | $230,300 |
| Median gross rent B25064 | $1,238 | $1,197 | $1,033 |
| White, not Hispanic B03002 | 54.0% | 59.3% | 76.3% |
| Black B03002 | 25.2% | 22.0% | 10.9% |
| Hispanic or Latino B03002 | 12.5% | 11.4% | 5.2% |
| Asian B03002 | 2.8% | 1.8% | 2.1% |
| American Indian and Alaska Native B03002 | 0.1% | 0.1% | 0.2% |
Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Kansas City, MO.
Comments